Get the latest news alerts: at Twitter.

Local Tech Wire

WILMINGTON, N.C. – How effective is the Food and Drug Administration’s system for monitoring adverse reactions to products?

(Nasdaq: PPDI) has won a $2.7 million contract to measure the effectiveness of the post-market surveillance system operated by the FDA’s Center for Drug Evaluation and Research.

The federal program launched in 2008.

PPD will rely on its experience in conducting clinical trials and drug development as a contract resource organization for life science companies around the world.

“Epidemiology is important to evaluating drug safety risks, and we are pleased the FDA recognized our strong capabilities and commitment to patient safety and regulatory compliance,” said Christine Dingivan, chief medical officer at PPD. “The contract enables us to assist the FDA in this important endeavor and demonstrates our breadth of drug safety and pharmacoepidemiology services.”